Sentact, a leading company in healthcare technology, analytics, and services focused on transforming patient care, has appointed Nicholas Testa, MD, as its new Chief Clinical Officer. In this role, Dr. Testa will guide the company’s clinical vision and work closely with partners to drive measurable improvements in patient outcomes and operational excellence.
Health Technology Insights: FuturHealth Adds Wegovy Pill to Its Wellness Solutions
Dr. Testa brings nearly 20 years of experience in healthcare, with a strong background in enhancing clinical operations, safety, quality, and patient experience. He joins Sentact’s executive leadership team to help shape strategic initiatives and represent the perspective of clinical leaders. Daniel Hart, CEO of Sentact, stated that Dr. Testa’s extensive track record of improving clinical operations and implementing best practices makes him a vital addition as the company continues to redefine the path to exceptional care.
In his new position, Dr. Testa will leverage his clinical expertise to support Sentact’s full portfolio of products and services, focusing on initiatives that advance safety, quality, and the alignment of technology with real-world clinical workflows. Dr. Testa expressed his enthusiasm about joining Sentact, highlighting the company’s integrated approach that provides actionable insights across healthcare organizations. He emphasized his commitment to collaborating with partners to improve performance, strengthen safety, and achieve better outcomes for patients and communities.
Health Technology Insights: Study Confirms AISAP AI Can Detect Heart Disease from Ultrasound
Prior to joining Sentact, Dr. Testa held several leadership roles, including Regional Chief Medical Officer at CommonSpirit Health in California, Chief Physician Executive at Dignity Health, Chief Medical Officer at Providence St. Joseph Medical Center, and Associate Medical Director at LAC+USC Medical Center. He also serves as an Adjunct Voluntary Professor at USC, where he continues to teach undergraduates, medical students, and residents in areas such as safety, quality, process improvement, and physician leadership.
Dr. Testa’s appointment aligns with Sentact’s recent strategic acquisitions aimed at advancing patient safety at scale and reinforces the company’s ongoing commitment to delivering measurable improvements in care quality and clinical outcomes nationwide.
Health Technology Insights: Genentech Reports Positive Phase II Results for Obesity Drug CT-388
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
